Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$159.67 USD
+6.55 (4.28%)
Updated May 1, 2024 04:00 PM ET
After-Market: $160.30 +0.63 (0.39%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Krystal Biotech, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 10.93 | -139.98 | -69.57 | -32.17 | -19.09 |
Depreciation/Amortization & Depletion | 3.73 | 4.06 | 2.77 | 1.85 | 0.97 |
Net Change from Assets/Liabilities | -37.88 | 2.81 | 2.05 | 0.93 | -1.91 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -65.58 | 32.54 | 16.81 | 3.31 | 1.31 |
Net Cash From Operating Activities | -88.80 | -100.57 | -47.94 | -26.08 | -18.71 |
Property & Equipment | 88.20 | -52.98 | -68.34 | -14.84 | -6.40 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -5.56 | -61.10 | -158.43 | 3.66 | 1.43 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 82.64 | -114.08 | -226.77 | -11.18 | -4.97 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 203.50 | 36.00 | 355.65 | 118.02 | 107.53 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.75 | -0.65 | -7.96 | 0.00 | 0.00 |
Net Cash from Financing Activities | 202.75 | 35.35 | 347.69 | 118.02 | 107.53 |
Effect of Exchange Rate Changes | -0.16 | -0.04 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 196.43 | -179.35 | 72.98 | 80.76 | 83.84 |
Cash at Beginning of Period | 161.90 | 341.25 | 268.27 | 187.51 | 103.67 |
Cash at End of Period | 358.33 | 161.90 | 341.25 | 268.27 | 187.51 |
Diluted Net EPS | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 |
Fiscal Year End for Krystal Biotech, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 10.93 | 2.24 | -78.51 | -45.30 |
Depreciation/Amortization & Depletion | NA | 3.73 | 2.57 | 1.74 | 0.71 |
Net Change from Assets/Liabilities | NA | -37.88 | -12.17 | -2.98 | 8.93 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -65.58 | -74.21 | 19.40 | 9.51 |
Net Cash From Operating Activities | NA | -88.80 | -81.57 | -60.35 | -26.16 |
Property & Equipment | NA | 88.20 | 90.05 | -8.17 | -5.38 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -5.56 | 2.75 | -4.22 | 8.94 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 82.64 | 92.80 | -12.39 | 3.56 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 203.50 | 200.88 | 187.49 | 2.22 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.75 | -0.75 | -0.75 | -0.75 |
Net Cash from Financing Activities | NA | 202.75 | 200.13 | 186.74 | 1.47 |
Effect of Exchange Rate Changes | NA | -0.16 | -0.02 | -0.03 | -0.04 |
Net Change In Cash & Equivalents | NA | 196.43 | 211.34 | 113.98 | -21.16 |
Cash at Beginning of Period | NA | 161.90 | 161.90 | 161.90 | 161.90 |
Cash at End of Period | NA | 358.33 | 373.24 | 275.88 | 140.75 |
Diluted Net EPS | NA | 0.61 | 2.79 | -1.25 | -1.76 |